Document Detail


Enalaprilat in acute myocardial infarction: tolerability and effects on the renin-angiotensin system.
MedLine Citation:
PMID:  1657799     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
We treated 48 patients with intravenous enalaprilat within 24 hours from the onset of acute myocardial infarction. Concomitant therapy included thrombolytic treatment (29), intravenous metoprolol (34), intravenous nitroglycerin (16) and intravenous furosemide (15). The first 40 patients included had systolic blood pressure at baseline greater than or equal to 110 mmHg. Intravenous bolus injections of 0.2-1.2 mg (mean 1.0 mg) enalaprilat in one hour were given to 20 patients and an intravenous infusion of 1 mg over two hours was administered to another 20 patients, as well as to a separate group of 8 patients with systolic blood pressure between 100-109 mmHg at baseline. The infusion was stopped in five cases when the systolic blood pressure fell below 100 and 90 mmHg, respectively, in the two infusion groups. No hypotensive reactions were symptomatic. Blood pressure decreased from a mean of 134/82, 131/79 and 106/72 mmHg to a minimum of 117/71, 118/73 and 97/63 mmHg, respectively, in the three groups. Almost complete suppression of plasma angiotensin converting enzyme activity was achieved within 30 minutes. No significant changes were found in plasma levels of angiotensin II, renin activity or atrial natriuretic peptide between baseline and 24 hours. Treatment was continued with oral enalapril 2.5-10 mg/day, which was generally well tolerated. We conclude that intravenous and oral enalapril added to conventional therapy in the early phase of acute myocardial infarction is well tolerated in selected patients, but should be carefully titrated.
Authors:
A Sigurdsson; P Held; G Andersson; K Swedberg
Related Documents :
10078539 - Sildenafil citrate and blood-pressure-lowering drugs: results of drug interaction studi...
2477339 - The safety and efficacy of terazosin for the treatment of benign prostatic hyperplasia.
9861299 - Beneficial effects of long-term selective endothelin type a receptor blockade in canine...
3620279 - Placebo does not lower ambulatory blood pressure.
7066169 - The addition of prazosin to standard triple therapy in the treatment of severe hyperten...
2971549 - 24-hour control of blood pressure by once daily doxazosin: a multicentre double-blind c...
17137809 - Wall stress analysis in small asymptomatic, symptomatic and ruptured abdominal aortic a...
9375989 - Invasive haemodynamic monitoring: concepts and practical approaches.
19948619 - Continuous monitoring of cerebrovascular pressure reactivity after traumatic brain inju...
Publication Detail:
Type:  Clinical Trial; Comparative Study; Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  International journal of cardiology     Volume:  33     ISSN:  0167-5273     ISO Abbreviation:  Int. J. Cardiol.     Publication Date:  1991 Oct 
Date Detail:
Created Date:  1991-12-20     Completed Date:  1991-12-20     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  8200291     Medline TA:  Int J Cardiol     Country:  NETHERLANDS    
Other Details:
Languages:  eng     Pagination:  115-24     Citation Subset:  IM    
Affiliation:
Department of Medicine, Ostra Hospital, University of Göteborg, Sweden.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Blood Pressure / drug effects
Enalaprilat / administration & dosage,  therapeutic use*
Female
Furosemide / therapeutic use
Humans
Infusions, Intravenous
Injections, Intravenous
Male
Metoprolol / therapeutic use
Middle Aged
Myocardial Infarction / drug therapy*
Nitroglycerin / therapeutic use
Renin-Angiotensin System / drug effects*
Thrombolytic Therapy
Chemical
Reg. No./Substance:
37350-58-6/Metoprolol; 54-31-9/Furosemide; 55-63-0/Nitroglycerin; 84680-54-6/Enalaprilat

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The response to epidermal growth factor of human maxillary tumor cells in terms of tumor growth, inv...
Next Document:  Attenuated renal excretory response to atrial natriuretic peptide in congestive heart failure in man...